Smith & Nephew reported new clinical outcomes for its flagship JOURNEY II BCS knee.
In a large, multi-center retrospective patient study, new clinical evidence represented positive mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants, including:
~1% of patients required major revision out to six years.
No major or minor revision of any patient four years or more post-op.
Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).
Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at six years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS total knee arthroplasty procedures.
JOURNEY II launched in late 2011 and has totaled >150,000 procedures globally.
Smith & Nephew reported new clinical outcomes for its flagship JOURNEY II BCS knee.
In a large, multi-center retrospective patient study, new clinical evidence represented positive mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants, including:
Smith & Nephew reported new clinical outcomes for its flagship JOURNEY II BCS knee.
In a large, multi-center retrospective patient study, new clinical evidence represented positive mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants, including:
~1% of patients required major revision out to six years.
No major or minor revision of any patient four years or more post-op.
Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).
Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at six years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS total knee arthroplasty procedures.
JOURNEY II launched in late 2011 and has totaled >150,000 procedures globally.
Copy to clipboard 
